CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial
Link to full article Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in […]